Pharmafile Logo

News and Press Releases

Gilead extends partnership with NHS England to eliminate hepatitis C by 2025

Since the commencement of the Strategic Procurement agreement in 2019, Gilead has worked in partnership with NHS England, non-profit organisations, and industry to help treat and cure over 84,000 people...

Category: Other, Pharmaceutical
Posted: April 8, 2024

Gilead Sciences, Inc

Kite Presents New Data for Yescarta (axicabtagene ciloleucel) CAR T-cell Therapy Highlighting Manufacturing Excellence and Cost-Effectiveness in the US

Data Highlights Industry-leading Manufacturing Success Rates for US Axicabtagene Ciloleucel Patients from Launch to Present Data Also Supports Cost-effectiveness of Axicabtagene Ciloleucel Versus Bispecific Antibodies 16 February 2024 – Stockley...

Category: BioManufacturing
Posted: February 21, 2024

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Gilead Sciences Strengthens Commitment to Inflammatory Disease with New Research Centre

14 February 2024 -- Oxford, UK -- On 14 February, Gilead Sciences held a ribbon-cutting event to celebrate the opening of its new research site at the Business Park in...

Category: BioManufacturing
Posted: February 14, 2024

Gilead Sciences, Inc

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s TECARTUS (brexucabtagene autoleucel) in patients with aggressive blood cancers

At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-term Response in Adult Patients with Relapsed/Refractory(R/R) Mantle Cell Lymphoma (MCL) Real-world...

Category: Clinical Trials
Posted: December 12, 2023

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Kite’s CAR T-Cell Therapy YESCARTA (Axicabtagene Ciloleucel) Compared with Bispecifics in R/R DLBCL in Two Analyses at ESMO 2023

23 October 2023 -- Stockley Park, UK -- Kite, a Gilead Company, today announced results from two indirect comparative analyses of its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) versus bispecific...

Category: Clinical Trials
Posted: October 23, 2023

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Gilead and Kite Oncology  Present Important Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

– Real-World Evidence and New Clinical Analysis Support the Role of Trodelvy (sacituzumab govitecan-hziy) in Metastatic Breast Cancers – New Data Demonstrate Potential of Sacituzumab Govitecan in Small Cell Lung...

Category: Pharmaceutical
Posted: October 16, 2023

Gilead Sciences, Inc

Kite’s CAR T-Cell Therapy Accepted for Use on the NHS in Scotland to Treat Aggressive Form of Blood Cancer

First CAR T-cell therapy for adult (26+) patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) reimbursed in Scotland 9 October 2023 -- London, UK -- Gilead Sciences...

Category: Pharmaceutical
Posted: October 9, 2023

Gilead Sciences, Inc